Home›Research›Compare›BPC-157 vs PT-141
Peptide ComparisonBPC-157 vs PT-141
BPC-157
Body Protection Compound 157
Half-life: Under 30 minutes (plasma); no human PK data
635 providers listed
PT-141
Bremelanotide
Half-life: 2–3 hours
290 providers listed
BPC-157 and PT-141 target different goals — BPC-157 for tissue repair across tendon, muscle, nerve, and gut — most broadly studied recovery peptide, PT-141 for centrally mediated sexual arousal via MC3R and MC4R agonism. They're compared here for reference, not as direct substitutes.
BPC-157
Evidence
Half-life
Under 30 minutes (plasma); no human PK data
PT-141
Evidence
Half-life
2–3 hours
BPC-157 and PT-141 target different goals — BPC-157 for Tissue Repair, PT-141 for Reproductive & Hormonal. They're compared here for reference; there isn't a single “better” choice between them.
BPC-157
PT-141
BPC-157
Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery.
Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury.
BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and…
Unilateral Adrenalectomy, and the Stable Pentadecapeptide BPC 157 as Therapy in Rats-A Cytoprotection Approac…
+6 more
PT-141
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Bremelanotide: First Approval
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications…
+3 more
About BPC-157
BPC-157 is believed to accelerate angiogenesis and upregulate growth hormone receptors locally at injury sites. It appears to promote fibroblast migration and collagen synthesis, contributing to faster tissue remodelling. Animal studies suggest systemic effects via modulation of the dopaminergic and serotonergic systems, though human data remain limited.
About PT-141
PT-141 is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly within the hypothalamus. Unlike peripherally acting agents, it modulates sexual arousal at the CNS level via dopaminergic pathways, independent of vascular mechanisms. Bremelanotide received FDA approval as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
BPC-157
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
global — WADA
BPC-157 is on the WADA Prohibited List at all times (S0, Non-Approved Substances), effective 1 January 2022. It has no FDA approval and no adequate human clinical trial.
sourcePT-141
Source: FDA label
FDA prescribing information for bremelanotide identifies transient blood pressure elevation as the primary safety concern. Baseline cardiovascular assessment and BP monitoring are recommended.
BPC-157
GHK-Cu
Research suggests GHK-Cu and BPC-157 may produce complementary tissue repair and anti-inflammatory effects when combined. GHK-Cu is studied for copper-dependent collagen synthesis and antioxidant gene activation, while BPC-157 supports angiogenesis and growth factor expression.
TB-500
Research suggests BPC-157 and TB-500 may produce enhanced tissue repair effects when combined. BPC-157 is studied for angiogenesis and gut-protective properties, while TB-500 promotes actin assembly and cell migration — complementary mechanisms in healing models.
Anticoagulants / blood thinners
Research notes that BPC-157 promotes angiogenesis and may influence platelet and vascular function in healing models. Combined use with anticoagulant medications may warrant monitoring. Consult your prescriber before combining.
PT-141
Oxytocin
Research suggests PT-141 and Oxytocin may produce complementary sexual health effects when combined. PT-141 activates central melanocortin receptors involved in arousal signaling, while oxytocin modulates bonding, reward, and peripheral reproductive pathways.
Antihypertensive medications
Research notes that PT-141 may influence cardiovascular hemodynamics via central melanocortin pathways. Combined use with antihypertensive medications may require monitoring. Consult your prescriber before combining.
BPC-157
PT-141
Where to source these peptides
BPC-157
635 listed
Browse directory →
Providers offeringPT-141
290 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
Related Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). BPC-157 vs PT-141 — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/bpc-157/pt-141